Risultati della ricerca - Giovanni Musso

Raffina i risultati
  1. 1
    Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders

    Gut microbiota as a regulator of energy homeostasis and ectopic fat deposition: mechanisms and implications for metabolic disorders di Giovanni Musso, Roberto Gambino, Maurizio Cassader

    Pubblicazione 2010
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  2. 2
    Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis

    Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis di Giovanni Musso, Roberto Gambino, Maurizio Cassader

    Pubblicazione 2012
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  3. 3
    Non‐alcoholic fatty liver disease from pathogenesis to management: an update

    Non‐alcoholic fatty liver disease from pathogenesis to management: an update di Giovanni Musso, Roberto Gambino, Maurizio Cassader

    Pubblicazione 2009
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  4. 4
    Obesity, Diabetes, and Gut Microbiota

    Obesity, Diabetes, and Gut Microbiota di Giovanni Musso, Roberto Gambino, Maurizio Cassader

    Pubblicazione 2010
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  5. 5
    Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease

    Emerging Molecular Targets for the Treatment of Nonalcoholic Fatty Liver Disease di Giovanni Musso, Roberto Gambino, Maurizio Cassader

    Pubblicazione 2010
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  6. 6
    PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease

    PNPLA3 rs738409 and TM6SF2 rs58542926 gene variants affect renal disease and function in nonalcoholic fatty liver disease di Giovanni Musso, Maurizio Cassader, Roberto Gambino

    Pubblicazione 2014
    Testo
    Carta
    Aggiungi alla lista
    Salvato in:
  7. 7
    A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD

    A single-letter change in an acronym: signals, reasons, promises, challenges, and steps ahead for moving from NAFLD to MAFLD di Yusuf Yılmaz, Christopher D. Byrne, Giovanni Musso

    Pubblicazione 2020
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  8. 8
    A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease

    A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease di Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano

    Pubblicazione 2010
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  9. 9
    Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of randomised trials

    Impact of current treatments on liver disease, glucose metabolism and cardiovascular risk in non-alcoholic fatty liver disease (NAFLD): a systematic review and meta-analysis of ran... di Giovanni Musso, Maurizio Cassader, F. Rosina, Roberto Gambino

    Pubblicazione 2012
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  10. 10
    A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials

    A novel approach to control hyperglycemia in type 2 diabetes: Sodium glucose co-transport (SGLT) inhibitors. Systematic review and meta-analysis of randomized trials di Giovanni Musso, Roberto Gambino, Maurizio Cassader, Gianfranco Pagano

    Pubblicazione 2011
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  11. 11
    Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis

    Thiazolidinediones and Advanced Liver Fibrosis in Nonalcoholic Steatohepatitis di Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino

    Pubblicazione 2017
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  12. 12
    Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis

    Bioactive Lipid Species and Metabolic Pathways in Progression and Resolution of Nonalcoholic Steatohepatitis di Giovanni Musso, Maurizio Cassader, Elena Paschetta, Roberto Gambino

    Pubblicazione 2018
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  13. 13
    Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials

    Efficacy and safety of dual SGLT 1/2 inhibitor sotagliflozin in type 1 diabetes: meta-analysis of randomised controlled trials di Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  14. 14
    Diabetic ketoacidosis with SGLT2 inhibitors

    Diabetic ketoacidosis with SGLT2 inhibitors di Giovanni Musso, Francesca Saba, Maurizio Cassader, Roberto Gambino

    Pubblicazione 2020
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  15. 15
    Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver

    Interactions among bone, liver, and adipose tissue predisposing to diabesity and fatty liver di Giovanni Musso, Elena Paschetta, Roberto Gambino, Maurizio Cassader, Federica Molinaro

    Pubblicazione 2013
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  16. 16
    Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH?

    Polymorphism in microsomal triglyceride transfer protein: A link between liver disease and atherogenic postprandial lipid profile in NASH? di Roberto Gambino, Maurizio Cassader, Gianfranco Pagano, Marilena Durazzo, Giovanni Musso

    Pubblicazione 2007
    Testo Testo
    Artigo
    Aggiungi alla lista
    Salvato in:
  17. 17
    Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution

    Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution di Giovanni Musso, Roberto Gambino, Maurizio Cassader, Elena Paschetta, Antonio Sircana

    Pubblicazione 2018
    Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  18. 18
    Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma

    Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma di Antonio Sircana, Elena Paschetta, Francesca Saba, Federica Molinaro, Giovanni Musso

    Pubblicazione 2019
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  19. 19
    Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression

    Assessing the risk of ketoacidosis due to sodium-glucose cotransporter (SGLT)-2 inhibitors in patients with type 1 diabetes: A meta-analysis and meta-regression di Giovanni Musso, Antonio Sircana, Francesca Saba, Maurizio Cassader, Roberto Gambino

    Pubblicazione 2020
    Testo Testo
    Revisão
    Aggiungi alla lista
    Salvato in:
  20. 20
    Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dysregulated enteroadipocyte axis as a novel feature of fatty liver

    Prolonged saturated fat–induced, glucose-dependent insulinotropic polypeptide elevation is associated with adipokine imbalance and liver injury in nonalcoholic steatohepatitis: dys... di Giovanni Musso, Roberto Gambino, Giovanni Pacini, Franco De Michieli, Maurizio Cassader

    Pubblicazione 2009
    Testo
    Artigo
    Aggiungi alla lista
    Salvato in:

Strumenti per la ricerca: